Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 6. Nontaxane chemotherapies induce TMEM-dependent prometastatic changes in the breast cancer microenvironment. Nontaxane chemotherapies induce TMEM-dependent.

Published bySamuel Martini Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 6. Nontaxane chemotherapies induce TMEM-dependent prometastatic changes in the breast cancer microenvironment. Nontaxane chemotherapies induce TMEM-dependent."— Presentation transcript:

1 Fig. 6. Nontaxane chemotherapies induce TMEM-dependent prometastatic changes in the breast cancer microenvironment. Nontaxane chemotherapies induce TMEM-dependent prometastatic changes in the breast cancer microenvironment. (A) Experimental design and chemotherapy scheme. (B) Mouse models of breast carcinoma and cohort sizes. (C) Representative histological [hematoxylin and eosin (H&E); left column] and TMEM IHC sections (right column) from MMTV-PyMT mice receiving doxorubicin/cyclophosphamide treatment or vehicle control, as shown in (A). Scale bar, 50 μm. (D) TMEM score in MMTV-PyMT mice treated with either vehicle control or doxorubicin/cyclophosphamide. Mann-Whitney U test. (E) CTCs per milliliter of blood collected before sacrifice (day 15). Values normalized to the control group in each case, to account for intercohort variability. Mann-Whitney U test. (F) Proportion of perivascular TIE2hi/VEGFhi macrophages among all IBA1+ macrophages, quantified in MMTV-PyMT mice treated with either doxorubicin/cyclophosphamide or vehicle control. Mann-Whitney U test. George S. Karagiannis et al., Sci Transl Med 2017;9:eaan0026 Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works

Download ppt "Fig. 6. Nontaxane chemotherapies induce TMEM-dependent prometastatic changes in the breast cancer microenvironment. Nontaxane chemotherapies induce TMEM-dependent."

Similar presentations

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.
Fibroblast activation in WT and NFATc2-deficient mice.

Fibroblast activation in WT and NFATc2-deficient mice.
Fig. 3. Paclitaxel promotes TMEM-dependent vascular permeability, cancer cell dissemination, and metastasis in breast cancer. Paclitaxel promotes TMEM-dependent.

Fig. 3. Paclitaxel promotes TMEM-dependent vascular permeability, cancer cell dissemination, and metastasis in breast cancer. Paclitaxel promotes TMEM-dependent.
Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.
Splenic CD169+ macrophages trap and prevent early Lm replication and spread. Splenic CD169+ macrophages trap and prevent early Lm replication and spread.

Splenic CD169+ macrophages trap and prevent early Lm replication and spread. Splenic CD169+ macrophages trap and prevent early Lm replication and spread.
FIP200 loss links to poor autophagy and high apoptosis in naïve T cells in tumor. FIP200 loss links to poor autophagy and high apoptosis in naïve T cells.

FIP200 loss links to poor autophagy and high apoptosis in naïve T cells in tumor. FIP200 loss links to poor autophagy and high apoptosis in naïve T cells.
FIP200 deficiency alters mitochondria activation and ROS production in T cells. FIP200 deficiency alters mitochondria activation and ROS production in.

FIP200 deficiency alters mitochondria activation and ROS production in T cells. FIP200 deficiency alters mitochondria activation and ROS production in.
Cytotoxicity of MSP samples to normal and cancer cell lines.

Cytotoxicity of MSP samples to normal and cancer cell lines.
CD8α+ DC-deficient mice are highly susceptible to Lm infection in the absence of CD169+ macrophages. CD8α+ DC-deficient mice are highly susceptible to.

CD8α+ DC-deficient mice are highly susceptible to Lm infection in the absence of CD169+ macrophages. CD8α+ DC-deficient mice are highly susceptible to.
CD169+ macrophages play a critical role in mediating innate immune cell reorganization. CD169+ macrophages play a critical role in mediating innate immune.

CD169+ macrophages play a critical role in mediating innate immune cell reorganization. CD169+ macrophages play a critical role in mediating innate immune.
TPAD controller performance for three force components.

TPAD controller performance for three force components.
Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.
Therapeutic effects of TIP60 allosteric modification in DSS-induced colitis. Therapeutic effects of TIP60 allosteric modification in DSS-induced colitis.

Therapeutic effects of TIP60 allosteric modification in DSS-induced colitis. Therapeutic effects of TIP60 allosteric modification in DSS-induced colitis.
Three different types of transfer functions with a codomain of [0,1].

Three different types of transfer functions with a codomain of [0,1].
Cytotoxic therapy induces CSF1-dependent macrophage recruitment.

Cytotoxic therapy induces CSF1-dependent macrophage recruitment.
The TGF-β pathway is activated in the skin after C

The TGF-β pathway is activated in the skin after C
Fig. 7. NAC in breast cancer patients promotes TMEM assembly and increased MENAINV expression. NAC in breast cancer patients promotes TMEM assembly and.

Fig. 7. NAC in breast cancer patients promotes TMEM assembly and increased MENAINV expression. NAC in breast cancer patients promotes TMEM assembly and.
FIP200 loss links to poor autophagy and high apoptosis in naïve T cells in tumor. FIP200 loss links to poor autophagy and high apoptosis in naïve T cells.

FIP200 loss links to poor autophagy and high apoptosis in naïve T cells in tumor. FIP200 loss links to poor autophagy and high apoptosis in naïve T cells.
Group data during free walking between sessions 1 and 16.

Group data during free walking between sessions 1 and 16.
Fig. 7 Correlation of NHP and human ISGs.

Fig. 7 Correlation of NHP and human ISGs.

Similar presentations

Ads by Google